CME Group (NASDAQ:CME) Shares Unloaded Rep. Julie Johnson

Representative Julie Johnson (D-Texas) recently sold shares of CME Group Inc. (NASDAQ:CME). In a filing disclosed on January 15th, the Representative disclosed that they had sold between $1,001 and $15,000 in CME Group stock on December 18th. The trade occurred in the Representative’s “CHASE BROKERAGE ACCOUNT (3935)” account.

Representative Julie Johnson also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Texas Instruments (NASDAQ:TXN) on 12/18/2025.
• Sold $1,001 – $15,000 in shares of UnitedHealth Group (NYSE:UNH) on 12/18/2025.
• Sold $1,001 – $15,000 in shares of General Dynamics (NYSE:GD) on 12/18/2025.
• Sold $1,001 – $15,000 in shares of PepsiCo (NASDAQ:PEP) on 12/18/2025.
• Sold $1,001 – $15,000 in shares of Dover (NYSE:DOV) on 12/18/2025.
• Sold $1,001 – $15,000 in shares of Philip Morris International (NYSE:PM) on 12/18/2025.
• Sold $1,001 – $15,000 in shares of Johnson & Johnson (NYSE:JNJ) on 12/18/2025.
• Sold $1,001 – $15,000 in shares of Bank of America (NYSE:BAC) on 12/18/2025.
• Sold $1,001 – $15,000 in shares of Walmart (NASDAQ:WMT) on 12/18/2025.
• Sold $1,001 – $15,000 in shares of Republic Services (NYSE:RSG) on 12/18/2025.

CME Group Stock Up 2.5%

Shares of CME stock opened at $279.44 on Monday. CME Group Inc. has a one year low of $230.19 and a one year high of $290.79. The company has a debt-to-equity ratio of 0.12, a current ratio of 1.02 and a quick ratio of 1.02. The stock has a fifty day moving average price of $274.20 and a 200 day moving average price of $271.79. The stock has a market cap of $100.77 billion, a P/E ratio of 27.08, a price-to-earnings-growth ratio of 3.15 and a beta of 0.27.

CME Group (NASDAQ:CME) last announced its quarterly earnings data on Wednesday, October 22nd. The financial services provider reported $2.68 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.63 by $0.05. CME Group had a net margin of 58.84% and a return on equity of 14.61%. The company had revenue of $1.54 billion during the quarter, compared to analysts’ expectations of $1.56 billion. During the same quarter in the prior year, the company posted $2.68 EPS. The business’s revenue was down 3.0% on a year-over-year basis. Analysts predict that CME Group Inc. will post 10.49 earnings per share for the current year.

CME Group Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, December 30th. Investors of record on Friday, December 12th were given a $1.25 dividend. This represents a $5.00 annualized dividend and a yield of 1.8%. The ex-dividend date of this dividend was Friday, December 12th. CME Group’s dividend payout ratio (DPR) is 48.45%.

Trending Headlines about CME Group

Here are the key news stories impacting CME Group this week:

• Positive Sentiment: CME plans to add Cardano (ADA), Chainlink (LINK) and Stellar (XLM) futures — standard and micro contracts — boosting crypto product breadth and capital‑efficient tools for clients; listing targeted for Feb. 9 pending review, which could lift futures trading volumes and fee revenue. CME Group Expands Crypto Futures With Cardano, Chainlink, and Stellar
• Positive Sentiment: TD Cowen upgraded CME to “Buy”, signaling constructive analyst sentiment that supports upside and likely helped investor confidence. TD Cowen Upgrades CME Group (NASDAQ:CME) to “Buy”
• Positive Sentiment: CME is introducing a new, smaller silver futures contract to capture surging retail interest in silver — a product move that can broaden participation and boost notional volumes in metals. Silver Gets a Major Upgrade: CME to Launch New Futures as Retail Demand Hits Record Levels
• Neutral Sentiment: Jefferies trimmed its price target slightly (from $304 to $302) but kept a “Buy” rating — modestly lowering upside but still supportive. Jefferies Adjusts Price Target on CME Group
• Neutral Sentiment: Morgan Stanley cut its price target by $1 to $319 while retaining an “Overweight” rating — a slight tweak that keeps a bullish stance but marginally lowers modeled upside. Morgan Stanley Lowers CME Price Target
• Neutral Sentiment: Analyst previews and coverage notes (e.g., “Here’s What to Expect From CME Group’s Next Earnings Report”) keep focus on volumes/fee trends and macro volatility — useful context but not immediate catalysts. Here’s What to Expect From CME Group’s Next Earnings Report
• Negative Sentiment: Goldman Sachs nudged its target slightly lower (from $265 to $264) and maintains a “Sell” rating — a visible negative outlier that can weigh on sentiment among more cautious investors. Goldman Sachs Adjusts CME Group Price Target

Insider Activity at CME Group

In other news, Director Harold Eugene Jr. Ford sold 1,000 shares of CME Group stock in a transaction on Monday, November 3rd. The stock was sold at an average price of $263.53, for a total value of $263,530.00. Following the completion of the sale, the director directly owned 1,091 shares of the company’s stock, valued at approximately $287,511.23. This trade represents a 47.82% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Terrence A. Duffy sold 25,000 shares of the business’s stock in a transaction on Thursday, December 11th. The stock was sold at an average price of $269.55, for a total value of $6,738,750.00. Following the sale, the chief executive officer owned 65,804 shares of the company’s stock, valued at approximately $17,737,468.20. The trade was a 27.53% decrease in their position. The SEC filing for this sale provides additional information. 0.30% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. JPMorgan Chase & Co. upped their target price on shares of CME Group from $252.00 to $256.00 and gave the company an “underweight” rating in a research note on Tuesday, October 14th. Barclays lifted their price objective on CME Group from $280.00 to $304.00 and gave the company an “equal weight” rating in a report on Friday, December 12th. TD Cowen raised CME Group from a “hold” rating to a “buy” rating and increased their target price for the stock from $290.00 to $305.00 in a report on Wednesday, January 14th. Keefe, Bruyette & Woods raised their target price on CME Group from $283.00 to $287.00 and gave the stock a “market perform” rating in a research report on Monday, October 13th. Finally, Weiss Ratings reiterated a “buy (b+)” rating on shares of CME Group in a research report on Monday, December 29th. Ten analysts have rated the stock with a Buy rating, six have assigned a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $291.82.

Hedge Funds Weigh In On CME Group

Institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. increased its stake in shares of CME Group by 0.4% in the third quarter. Vanguard Group Inc. now owns 35,307,074 shares of the financial services provider’s stock valued at $9,539,618,000 after buying an additional 130,698 shares in the last quarter. Geode Capital Management LLC grew its holdings in CME Group by 3.6% during the 2nd quarter. Geode Capital Management LLC now owns 9,178,681 shares of the financial services provider’s stock worth $2,524,271,000 after acquiring an additional 319,899 shares during the last quarter. Norges Bank acquired a new stake in CME Group in the 2nd quarter valued at about $1,571,447,000. Ameriprise Financial Inc. increased its position in CME Group by 2.8% in the 3rd quarter. Ameriprise Financial Inc. now owns 4,812,914 shares of the financial services provider’s stock valued at $1,300,450,000 after acquiring an additional 130,848 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership lifted its position in shares of CME Group by 6.6% during the second quarter. Arrowstreet Capital Limited Partnership now owns 3,833,090 shares of the financial services provider’s stock worth $1,056,476,000 after purchasing an additional 238,522 shares in the last quarter. Institutional investors own 87.75% of the company’s stock.

About Representative Johnson

Julie Johnson (Democratic Party) is a member of the U.S. House, representing Texas’ 32nd Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027.

Johnson (Democratic Party) ran for election to the U.S. House to represent Texas’ 32nd Congressional District. She won in the general election on November 5, 2024.

Julie Johnson earned a B.A. in history and government from the University of Texas at Austin in 1987 and a J.D. from the University of Houston Law Center in 1991. Johnson’s career experience includes working as an attorney.

About CME Group

CME Group Inc is a global markets company that operates some of the world’s largest and most liquid derivatives exchanges, including the Chicago Mercantile Exchange (CME), the Chicago Board of Trade (CBOT), the New York Mercantile Exchange (NYMEX) and COMEX. The firm offers futures and options contracts across a broad range of asset classes — including interest rates, equity indexes, foreign exchange, energy, agricultural commodities and metals — and serves a diverse client base of institutional investors, commercial hedgers, brokers and retail participants.

The company’s core services include electronic trading on the CME Globex platform, central clearing through CME Clearing, and distribution of market data, indexes and analytics.